7
Participants
Start Date
June 30, 2008
Primary Completion Date
December 31, 2015
Study Completion Date
December 31, 2015
bevacizumab
Bevacizumab (10 mg/kg) will be given intravenously every other week starting one week before the first dose of BCNU. Treatment with both BCNU and bevacizumab for 6-months, after which the participant may continue to receive bevacizumab every 2 weeks for a maximum of one year and three additional cycles of BCNU.
carmustine
BCNU (200 mg/m2), will be given over 4 hours as a continuous intravenous infusion every 8 weeks. Treatment with both BCNU and bevacizumab for 6-months, after which the participant may continue to receive bevacizumab every 2 weeks for a maximum of one year and three additional cycles of BCNU.
University of California Davis Cancer Center, Sacramento
Collaborators (1)
National Cancer Institute (NCI)
NIH
Genentech, Inc.
INDUSTRY
University of California, Davis
OTHER